Trial Profile
Co-stimulation With Ipilimumab to Enhance Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Patients With Metastatic Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 11 Nov 2022
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Lifileucel (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
- Indications Malignant melanoma
- Focus Adverse reactions
- 08 Nov 2022 Planned End Date changed from 1 Dec 2022 to 15 Dec 2025.
- 18 Jan 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 20 Jan 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.